Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain

Description

A randomized study to determine safety and efficacy of single subcutaneous (SC) administration of HAL treatment in patients with CINP.

Conditions

Chemotherapy Induced Neuropathic Pain

Talk to us

Study Overview

On this page

Study Details

Study overview

A randomized study to determine safety and efficacy of single subcutaneous (SC) administration of HAL treatment in patients with CINP.

A Randomized, Double-Blind, Placebo Controlled, Multicenter, Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain

Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain

Condition
Chemotherapy Induced Neuropathic Pain
Intervention / Treatment

-

Contacts and Locations

Fountain Valley

Ark Clinical Research, Fountain Valley, California, United States, 92708

Atlanta

CenExel ACMR, Atlanta, Georgia, United States, 30331

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Male or female patients aged ≥18 years.
  • * Neuropathic pain has been present and is attributed to platinum and/or taxane chemotherapy.
  • * Patient has received a cancer chemotherapy regimen that included taxanes and/or platinum and has no active or discernible disease progression.
  • * Current neuropathic pain with symptoms similar to CINP but attributed to causes other than platinum or taxane chemotherapy.
  • * Patients who have received HAL at any time prior to screening.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Dogwood Therapeutics Inc.,

Study Record Dates

2026-08